Quick Answer
Travere Therapeutics, Inc. reported Net Income of -$25.55 million for fiscal year 2025.
Travere Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$25.55M | +92.1% |
| 2024 | -$321.55M | -188.6% |
| 2023 | -$111.40M | +60.0% |
| 2022 | -$278.48M | -54.6% |
| 2021 | -$180.09M | -6.3% |
| 2020 | -$169.43M | -15.7% |
| 2019 | -$146.43M | -42.6% |
| 2018 | -$102.68M | -71.9% |
| 2017 | -$59.73M | -24.7% |
| 2016 | -$47.90M | -140.9% |
| 2015 | $117.24M | +205.7% |
| 2014 | -$110.94M | -220.4% |
| 2013 | -$34.62M | -14.1% |
| 2012 | -$30.34M | -204580.3% |
| 2012 | -$14.8K | +35.6% |
| 2011 | -$23.0K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.71M | +146.9% | +301.5% |
| June 30, 2025 | -$12.76M | +81.9% | +69.1% |
| March 31, 2025 | -$41.23M | +69.7% | +24.8% |
| September 30, 2024 | -$54.81M | -136.4% | +22.2% |
| June 30, 2024 | -$70.41M | +17.8% | +48.3% |
| March 31, 2024 | -$136.06M | -57.6% | -190.3% |
| September 30, 2023 | $150.74M | +316.4% | +276.0% |
| June 30, 2023 | -$85.63M | -27.7% | +0.8% |
- Travere Therapeutics, Inc. showed an increase of +92.1% in Net Income compared to the prior fiscal year.
- Over the 2011–2025 period, Travere Therapeutics, Inc.’s net income has declined by 110863.4% (from -$23.0 thousand to -$25.55 million).
- The most recent figure is from Travere Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: